1. "Survivorship Research"
Formats
  1. Journal Article (8900)
  2. Meeting Abstract (5192)
  3. Book Section (571)
  4. Review (357)
  5. Editorial (225)
  6. Research Letter (132)
  7. Conference Paper (104)
  8. Correspondence (91)
  9. Guidelines (85)
  10. Miscellaneous (76)
  11. Book Whole (30)
Groups
  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (788)
  3. Michael Zelefsky (754)
  4. Sergio Giralt (684)
  5. Mark Robson (676)
  6. Joachim Yahalom (625)

More People

Years
  1. 2025 (231)
  2. 2024 (802)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (930)

More Years

Publications
  1. Journal of Clinical Oncology (1873)
  2. International Journal of Radiation Oncology, Biology, Physics (908)
  3. Blood (685)
  4. Annals of Surgical Oncology (599)
  5. Cancer Research (333)
  6. Cancer (331)

More Publications

Publishers
  1. Elsevier Inc. (2658)
  2. American Society of Clinical Oncology (2019)
  3. Springer (1542)
  4. Wiley Blackwell (806)
  5. Oxford University Press (787)
  6. American Society of Hematology (748)

More Publishers

Results (15763)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer
    Meeting Abstract

    Schrag, D.; Weiser, M. R.; Goodman, K. A.; Gonen, M.; Cercek, A.; Reidy, D. L.; Temple, L. K.; Wong, W. D.; Paty, P.; Saltz, L.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Effect of pelvic exenteration type and vaginal reconstruction on quality of life
    Meeting Abstract

    Rezk, Y.; Dao, F.; Hurley, K.; Carter, J.; Bochner, B.; Aubey, J.; Caceres, A.; Abu-Rustum, N.; Barakat, R. R.; Chi, D.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Celecoxib and aromatase activity in breast cancer: Results from a prospective randomized preoperative trial
    Meeting Abstract

    Port, E. R.; Subbaramaiah, K.; Brogi, E.; Sampson, M.; Panageas, K.; Dannenberg, A.; Hudis, C.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy
    Meeting Abstract

    Nardone, B.; Kaklamani, V. G.; Nicholson, K. M.; Newman, M.; Guitart, J.; Gerami, P.; Talarico, N.; Rademarker, A.; West, D. P.; Lacouture, M. E.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study
    Meeting Abstract

    Murphy, C.; Mallam, D.; Stein, S.; Patil, S.; Howard, J.; Sklarin, N. T.; Gemignani, M.; Hudis, C.; Seidman, A. D.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Dermatological toxicities associated with MEK 1/2 inhibitor AZD6244
    Meeting Abstract

    Myskowski, P.; Balagula, Y.; Barth, K.; Busam, K.; Lacouture, M. E.; Chapman, P. B.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Reactivation of chronic hepatitis B virus in cancer patients receiving immunosuppression: The case for screening
    Meeting Abstract

    Mendelsohn, R. B.; Nagula, S.; Taur, Y.; Kamboj, M.; Sepkowitz, K.; Zelenetz, A. D.; Ludwig, E.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC)
    Meeting Abstract

    Melisko, M. E.; Greenberg, S.; Dickler, M. N.; Moasser, M. M.; Scott, J. H.; DeLuca, A. N.; Moore, D. H.; Hudis, C.; Park, J. W.; Rugo, H. S.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy
    Meeting Abstract

    Ludwig, E.; Mendelsohn, R. B.; Taur, Y.; Kamboj, M.; Nagula, S.; Sepkowitz, K.; Zelenetz, A. D.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save